ResearchHub | Open Science Community

Junlong Wu

Author with expertise in Advancements in Prostate Cancer Research

Achievements

This user has not unlocked any achievements yet.

Key Stats

Upvotes received:

Publications:

(33% Open Access)

Cited by:

h-index:

i10-index:

Reputation

Biology

< 1%

Chemistry

< 1%

Economics

< 1%

How is this calculated?

Publications

Interlesional response heterogeneity is associated with the prognosis of abiraterone treatment in metastatic castration-resistant prostate cancer

Jian Pan et al.Aug 1, 2024

Interlesional response heterogeneity (ILRH) poses challenges to the treatment of metastatic castration-resistant prostate cancer (mCRPC). Currently, there are no prospective clinical trials exploring the prognostic significance of ILRH on paired positron emission tomography/computed tomography (PET/CT) in the context of abiraterone therapy.

Oncology

Internal Medicine

Paper

Oncology

Save

Protocol for CHAMPION study: a prospective study of maximal-cytoreductive therapies for patients with de novo metastatic hormone-sensitive prostate cancer who achieve oligopersistent metastases during systemic treatment with apalutamide plus androgen deprivation therapy

Beihe Wang et al.May 25, 2024

The proposed trial is to examine the feasibility of prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT)-guided cytoreduction plus apalutamide and androgen deprivation therapy (ADT) for newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) at oligometastatic state.

Paper

Save

Development and validation of the utLIFE-PC algorithm for noninvasive detection of prostate cancer in urine: A prospective, observational study

Sujun Han et al.Dec 1, 2024

Internal Medicine

Biomedical Engineering

Paper

Internal Medicine

Biomedical Engineering

Save